1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,150 | 6,400 | 10:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Agomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 13.10. | AgomAb Therapeutics NV - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 13.10. | AgomAb Therapeutics NV: Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease | 1 | GlobeNewswire (USA) | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.10. | H.C. Wainwright reiterates Agomab stock rating on trial data | 1 | Investing.com | ||
| 02.10. | H.C. Wainwright bestätigt Kaufempfehlung für Agomab nach Studiendaten | - | Investing.com Deutsch | ||
| 01.10. | Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial | 2 | Benzinga.com | ||
| 01.10. | AgomAb Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.10. | AgomAb Therapeutics NV: Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease | 257 | GlobeNewswire (Europe) | -- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn's disease (FSCD) patients -- -- Low annualized FSCD-related event... ► Artikel lesen | |
| 14.09. | AgomAb Therapeutics NV: Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study | 237 | GlobeNewswire (Europe) | -- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high... ► Artikel lesen | |
| 11.09. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.09. | Agomab: Aktionäre genehmigen neue Verwaltungsratsmitglieder und eine Anpassung der Optionsscheine | 1 | Investing.com Deutsch | ||
| 11.09. | Agomab: Aktionäre stimmen Berufungen in den Verwaltungsrat und Anpassung von Optionsscheinen zu | 1 | Investing.com Deutsch | ||
| 11.09. | Agomab shareholders approve board appointments, warrant adjustment | 1 | Investing.com | ||
| 11.09. | AgomAb Therapeutics NV: Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | 418 | GlobeNewswire (Europe) | Antwerp, Belgium, September 11, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced... ► Artikel lesen | |
| 25.08. | This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 1 | Benzinga.com | ||
| 25.08. | Piper Sandler initiates Agomab stock with Overweight rating | 3 | Investing.com | ||
| 25.08. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.08.2026 | 770 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.08.2026
Aktien
1 US00860C1027 AgomAb Therapeutics... ► Artikel lesen | |
| 10.08. | Agomab proposes two board members for shareholder vote | 1 | Investing.com | ||
| 10.08. | Agomab proposes two new board members, sets shareholder vote | 1 | Investing.com | ||
| 10.08. | AgomAb Therapeutics NV: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | 231 | GlobeNewswire (Europe) | Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,217 | -6,02 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,524 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| INFLARX | 1,205 | +10,65 % | InflaRx: 2027 - warum die nächsten Studien jetzt zählen | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| CARDIOL THERAPEUTICS | 0,923 | +0,98 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| GERON | 0,885 | +1,80 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| IBIO | 0,688 | -1,64 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| ARBUTUS BIOPHARMA | 3,370 | -1,75 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| IMMATICS | 5,840 | +1,74 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,230 | 0,00 % | Cellectar Biosciences GAAP EPS of -$0.46 beats by $0.10 |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +12,80 % bei einem Aktienkurs von 7,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.